alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_ENG.pdf

English (United States)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_Spanish_ESP_Public.pdf

Spanish (Spain)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_French_FRA.pdf

French (France)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_Greek.pdf

Greek (Greece)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_Italian.pdf

Italian (Italy)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_PRT.pdf

Portuguese (Portugal)

alnylam/studies/attachments/ALN-TTRSC04-004_Lay_Protocol_Synopsis_SWE.pdf

Swedish (Sweden)

The purpose of this study is to:

* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
* Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

TRANSTHYRETIN AMYLOIDOSIS (TTR)

hATTR-PN

Vutrisiran

Nucresiran

Clinical Trial Site

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)

The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.

The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome.

The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability.

The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening.

Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period

Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period